Ahn-Gook Pharmaceutical Q1 2026: Strong Earnings (+63% Op. Profit), Pipeline Progress

Consolidated revenue KRW 98.9B, operating profit KRW 16.0B (up 30.6% and 63.0% YoY)
Net profit KRW 12.4B, EPS KRW 1,089 (consolidated)
R&D expenses KRW 3.8B (3.85% of revenue); 4 items in pipeline (e.g., AG-1705) under approval/clinical trials
Formed KRW 13B fund with Mirae Asset Capital for new growth engines
Treasury stock: 12.86% (1,677,055 shares); dividend payable KRW 7.2B (separate)
Ongoing litigation for violation of Pharmaceutical Affairs Law (provision KRW 30M)